Physician profile
Evan Sehgal
NPI 1982671871
$60,033.83
in general payments reported to CMS, 2019-2025
31 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $4,484 · 2021: $11K · 2022: $32K · 2023: $1,833 · 2024: $7,169 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,976 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,335 · Travel and Lodging: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,976.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,335.00 |
| Travel and Lodging | $974.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $49,913.39 | 2020-2025 | Nexletol, Nexlizet |
| Medtronic, INC. | $1,513.22 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Mycarelink |
| Amgen INC. | $1,398.59 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $958.48 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $924.78 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $789.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $748.54 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Boston Scientific Corporation | $640.11 | 2020-2025 | Watchman Flx |
| Philips North America LLC | $478.87 | 2022-2025 | Mcot, (Ck7) Extended Holter, Extended Holter |
| Pfizer INC. | $446.73 | 2021-2025 | |
| Medtronic Vascular, INC. | $358.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $305.31 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $296.90 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $287.68 | 2022-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $242.43 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $173.95 | 2025 | Amvuttra, Onpattro |
| Heartflow, INC. | $144.08 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.58 | 2020-2023 | Lifevest |
| Novo Nordisk INC | $83.36 | 2021-2025 | Ozempic |
| Cvrx, INC. | $57.10 | 2024 | Barostim Neo System |
| W. L. Gore & Associates, INC. | $28.01 | 2022 | |
| Cardiva Medical, INC. | $21.49 | 2024 | Optowire |
| Abbott Laboratories | $17.93 | 2025 | Aveir |
| Bridgebio Pharma, INC. | $17.29 | 2025 | Attruby |
| Irhythm Technologies, INC. | $16.95 | 2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $16.27 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Lundbeck LLC | $13.89 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.50 | 2024 | |
| Lilly USA, LLC | $13.13 | 2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.